Integra Lifesciences Holdings Corp (IART) Shares Sold by Citigroup Inc.

Citigroup Inc. cut its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 72.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,421 shares of the life sciences company’s stock after selling 9,149 shares during the quarter. Citigroup Inc.’s holdings in Integra Lifesciences were worth $155,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in IART. Cardinal Capital Management boosted its stake in shares of Integra Lifesciences by 1.6% in the 4th quarter. Cardinal Capital Management now owns 17,899 shares of the life sciences company’s stock valued at $807,000 after purchasing an additional 287 shares during the last quarter. Retirement Systems of Alabama raised its holdings in Integra Lifesciences by 0.4% during the fourth quarter. Retirement Systems of Alabama now owns 91,666 shares of the life sciences company’s stock worth $4,134,000 after buying an additional 352 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Integra Lifesciences by 8.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,071 shares of the life sciences company’s stock worth $229,000 after buying an additional 412 shares during the last quarter. Strs Ohio raised its holdings in Integra Lifesciences by 7.4% during the fourth quarter. Strs Ohio now owns 7,187 shares of the life sciences company’s stock worth $324,000 after buying an additional 498 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in Integra Lifesciences by 1.1% during the fourth quarter. Arizona State Retirement System now owns 50,744 shares of the life sciences company’s stock worth $2,289,000 after buying an additional 572 shares during the last quarter. 83.91% of the stock is currently owned by institutional investors.

Several brokerages have recently commented on IART. BidaskClub downgraded shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. ValuEngine lowered shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Thursday, April 18th. Zacks Investment Research lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Oppenheimer cut their target price on shares of Integra Lifesciences from $70.00 to $65.00 and set an “outperform” rating for the company in a research report on Thursday. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $59.33.

In other news, major shareholder Richard E. Caruso sold 30,128 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $56.06, for a total transaction of $1,688,975.68. Following the sale, the insider now owns 143,384 shares in the company, valued at approximately $8,038,107.04. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Lisa Evoli sold 1,291 shares of Integra Lifesciences stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $55.90, for a total value of $72,166.90. Following the completion of the transaction, the insider now directly owns 4,968 shares of the company’s stock, valued at approximately $277,711.20. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.

Shares of Integra Lifesciences stock opened at $52.54 on Friday. The company has a market capitalization of $4.38 billion, a PE ratio of 21.71, a PEG ratio of 1.56 and a beta of 0.96. Integra Lifesciences Holdings Corp has a 52-week low of $42.14 and a 52-week high of $67.50. The company has a current ratio of 2.95, a quick ratio of 1.88 and a debt-to-equity ratio of 0.97.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.04. Integra Lifesciences had a net margin of 4.13% and a return on equity of 16.02%. The business had revenue of $359.69 million for the quarter, compared to analysts’ expectations of $361.12 million. During the same quarter in the previous year, the business posted $0.58 earnings per share. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. As a group, analysts predict that Integra Lifesciences Holdings Corp will post 2.68 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Integra Lifesciences Holdings Corp (IART) Shares Sold by Citigroup Inc.” was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/27/citigroup-inc-cuts-position-in-integra-lifesciences-holdings-corp-iart.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: Do investors pay a separate front-end load every time they buy additional shares?

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.